A peripherally acting cannabinoid receptor 1 antibody combined with semaglutide induced significant weight loss for adults ...
Danish pharma major Novo Nordisk has announced the launch of Ozempic (injectable semaglutide) in India. The popular ...
For Elizabeth Honigsberg, a general and bariatric surgeon and obesity and weight management specialist at Dartmouth Hitchcock Medical Center in Lebanon, combating obesity and the misconceptions that s ...
Schizophrenia spectrum disorders significantly increase cardiovascular and metabolic disease risks, partly due to antipsychotic-induced weight gain and glucose dysregulation.
The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...
Semaglutide medications like Ozempic and Wegovy can help lower the risk of heart and metabolic diseases in people with ...
Tantalizing results from small trials and anecdotes raised hopes that drugs like Ozempic could help. Despite setbacks, ...
Inflammation likely plays a key role in T2D outcomes, and various anti-inflammatory treatments may improve both T2D and its ...
Recently, the Delhi High Court refused to grant an interim injunction sought by Novo Nordisk, noting concerns of possible ...
Altimmune, Inc. nears key MASH data for pemvidutide—learn investor risks, potential rewards, and what the upcoming results ...
They’re definitely easier and more affordable than injectables, but do they work as well? Here’s what you need to know.
Khaleej Times on MSN
Wegovy shows liver health benefits in MASH patients beyond weight loss
Novo Nordisk’s Wegovy® (semaglutide 2.4 mg) was associated with liver health–related benefits not solely driven by weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results